> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Guidance on Impurity Standards For Fermentation-Based Antibiotics
- URL: https://www.fdaweb.com/guidance-on-impurity-standards-for-fermentation-based-antibiotics/
- Published: 2026-04-17T12:00:00.000Z
- Updated: 2026-09-14T13:37:37.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5161002

FDA has released a [draft guidance ](https://www.fda.gov/media/192017/download?ref=fdaweb.com)outlining how drugmakers should establish impurity specifications for antibiotics produced by fermentation and semi-synthetic processes, aiming to standardize quality expectations for a complex class of medicines. The CDER document provides recommendations for identifying, testing and setting acceptance criteria for impurities and degradation products in antibiotic drug substances and finished products.

The draft notes that FDA does not intend to apply the recommendations retroactively to already approved or marketed products, citing concerns about potential supply disruptions. However, manufacturers are encouraged to update impurity specifications when making significant changes, such as switching active ingredient suppliers.

Certain categories—such as microbiological contaminants, residual solvents and leachables—are excluded from the scope because they are addressed in other regulatory frameworks.

The agency emphasizes that manufacturers must establish scientifically sound specifications for impurities and degradation products as part of current good manufacturing practice requirements. This includes:

- Clearly listing identified and unidentified impurities and degradation products in both drug substance and drug product specifications
- Setting acceptance criteria based on identification thresholds and total impurity limits
- Validating analytical methods used to detect and quantify impurities, including demonstrating accuracy, precision and robustness

FDA also highlights the importance of fully characterizing antibiotic drug substances, which often consist of multiple structurally related active components rather than a single molecular entity.

Additionally, the guidance calls for a data-driven approach to setting impurity limits, drawing on clinical and nonclinical data, prior knowledge and comparisons to reference-listed drugs where applicable. Particular attention is given to potentially hazardous impurities, including nitrosamines and other compounds with mutagenic or carcinogenic potential. Manufacturers are advised to conduct risk assessments and follow existing ICH guidance for managing such risks.

For impurities exceeding established qualification thresholds, FDA recommends that sponsors provide additional safety justification, such as toxicology studies and mutagenicity assessments.